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outcome is comparable with pelvic exenteration surgery and it is 
better with longer interval between two radiation schedules. 
However, larger series and longer follow-up of clinical outcome and 
late toxicities is required for further validation of current promising 
results. 
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Purpose/Objective: The aim of this retrospective study was to 
investigate treatment results and toxicity profile of reirradiation 
treatment in inoperable patients with first local recurrence of cervical 
or vaginal cancer. Additional analysis of clinical and dosimetric 
parameters was undertaken in order to define prognostic factor in this 
cohort. 
Materials and Methods: Between 1997 and 2011, 20 patients have 
been treated at Brachytherapy Department in Warsaw for recurrent 
cervical (19) or vaginal (1) cancer. All patients were deemed 
inoperable or refused surgery. Median age of patients was 62 years 
(range 26-77). Three patients had adenocarcinoma, 16 - squamous cell 
carcinoma and one- carcinoma solidum undifferentiatum. Three 
patients were treated with combined EBRT and brachytherapy. In 9 
patients brachytherapy was associated with hyperthermia treatment. 
The main technique used in brachytherapy applications was 
interstitial (11 patients), followed by vaginal cylinder (6) or 
intraoperative (3). The median EQD2 dose calculated for reirradiation 
treatment was 48,8Gy (range 25-91), and median cumulative EQD2 
dose calculated for primary and reirratiation treatment was 133,5Gy 
(range 96,8-164,2). Early and late toxicity was scored with RTOG and 
RTOG/EORTC scales respectively. Kaplan-Meier estimates for overall 
survival(OS), disease free survival (DFS) and loco-reginal control (LC) 
were calculated. Mantel-Cox’s method was used to define the 
influence of clinical and dosimetric parameters on OS, DFS, LC and 
toxicity profile.  
Results: The 3-year OS (95%CI) was 68% (44%-91%). The 2-year DFS 
(95% CI) was 42.1% (19.4%-64.8%). The 2-year LC (95% CI) was 45.1% 
(21.6%-68.6%). According to Mantel-Cox’s analysis, the time to first 
local failure ≤12 months and tumour diameter > 3cm were both 
adverse prognostic factors affecting OS (p=0.001, 0,001 respectively), 
DFS (p=0.014,0,013 respectively) and LC (p=0.007, 0,005 
respectively). Acute toxicity was acceptable, with no grade 3-4 
radiation related toxic effects reported. GU and GI grade 3 late 
toxicity was observed in 2 patients (10%) and 1 patient (5%) 
respectively.  
Conclusions: Reirradiation with the use of high quality brachytherapy 
is a treatment option in recurrent cervical and vaginal cancers with 
potential for permanent cure. Low level of severe late complications 
encourages total dose escalationin order to increase the chance of 
cure. According to the results of this analysis patients with local 
recurrence diagnosed during the first year of follow up or tumour 
diameter > 3cm should not be treated with radiotherapy again.  
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Purpose/Objective: Chemoradiotherapy is the standard of care for 
locally advanced head and neck cancer (LAHNC). However, many 
elderly patients are unsuitable for this approach. We report our 
experience of altered fractionated radiotherapy (RT) as a potential 
means of treatment intensification for this population. 
Materials and Methods: A retrospective review was conducted on a 
prospectively assembled cohort of all newly diagnosed LAHNC (stage 
III-IV) in elderly patients (> 70 years old at the diagnosis) treated with 
RT alone in our institution between 1/1/2003 ~ 4/30/2010. RT 
regimens were not randomly assigned and were classified into 3 
categories: a) standard RT (sRT) [70 Gy in 35 fractions over 7 weeks 
(70 Gy/35f/7w)], b) moderated accelerated RT (mRT) over 5 or 6 
weeks (60 Gy/25f/5w, or 70 Gy/35f/6w), and c) very accelerated RT 
(vRT) over 4 weeks (64 Gy/40f/4w, twice daily). Appropriate 
supportive measures were provided during and after RT. Selective use 
of vRT was primarily in patients with good performance status but 
with bulky tumors. Overall survival (OS), locoregional control (LRC), 
distant control (DC), and actuarial late toxicity (>=Grade 3 by 
EORTC/RTOG criteria) were calculated and compared among the sRT, 
mRT and vRT cohorts. Multivariate analysis (MVA) identified predictors 
for OS and LRC. 
Results: A total of 294 patients were included (48 sRT, 178 mRT and 
68 vRT). Disease sites were: oropharynx (113, HPV positive 38, 
negative 32, unascertained 43), larynx (93), oral cavity (33), unknown 
primary (23), hypopharynx (25), and nasal cavity (7). Six patients (2 
sRT and 4 mRT) did not finish the RT and 77 patients (14 sRT, 46 mRT, 
17 vRT) had unplanned breaks during RT. The vRT patients were 
younger (median age: vRT 74.9, sRT 75.2, mRT 76.5 years, p<0.01). 
Smoking pack-years and the proportions of oropharyngeal cancer, T4 
and N2b-N3 category disease were similar among the 3 cohorts. Of the 
183 deaths, 24/35 (69%) sRT, 64/107 (60%) mRT, and 22/41 (53%) vRT 
cases died of their index cancer. 3-year outcomes for the 3 cohorts 
are listed in table 1. MVA revealed mRT was associated with better OS 
(HR 0.62, p=0.02) and LRC (HR 0.49, p<0.01) vs sRT, while vRT was 
also associated with better OS (HR 0.49, p<0.01) and marginally 
improved LRC vs sRT (HR 0.66, p=0.19) when controlling for T- & N-
category, age, smoking pack-years, and disease site. 
 
  
Conclusions: This non-randomized assigned cohort study demonstrates 
an association between altered fractionation RT schedules and 
outcome in elderly patients with LAHNC, without significantly 
increased late toxicity. The benefit of vRT is uncertain, since the 
observations are likely confounded by selection bias (bulkier tumor on 
the one hand and younger fitter patients on the other) and small 
sample size. With appropriate patient selection, altered fractionation 
RT is a valid treatment intensification option for the older population 
in the setting of appropriate supportive management during and 
following RT. 
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Purpose/Objective: To investigate the clinical value of the plasma 
EBV DNA (pEBV DNA) assay in patients with nasopharyngeal carcinoma 
(NPC) after curative treatment. 
S36  2nd ESTRO Forum 2013	
Materials and Methods: The inclusion criteria for this multi-center 
prospective study are (1) biopsy-proven NPC, (2) no distant 
metastasis, (3) in clinical remission after curative treatment 
(radiotherapy ± chemotherapy), (4) within 3 year after finishing 
radiotherapy. pEBV DNA concentration is monitored every 3 months. 
Detailed staging workups areperformed when abnormal pEBV DNA 
detected. All tumor recurrences are documented by imaging studies 
along with pathological verification if the lesions are accessible and 
patients agree. 
Results: From August 2011 to October2012, 252 patients were 
enrolled and 33 patients had abnormal pEBV DNA during follow-up 
visit. Thirty of 33 (91%) patients with elevated pEBV DNA have been 
proven as tumor relapse, whereas the remaining 219 patients with 
normal pEBV DNA level are showing no evidence of disease (P<0.0001). 
In addition, two-thirds (20/30) relapsed patients were detected in a 
symptomless state. 
Conclusions: pEBV DNA assay is a very encouraging tool in monitoring 
NPC patients after treatment.  
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Purpose/Objective: Recent studies showed that the dose distribution 
in certain anatomical structures, such as the pharyngeal constrictor 
muscles (PCM), are associated with the risk of radiation-induced 
dysphagia. In the normal swallowing process, larynx elevation and 
tongue retraction also play an important role. However, so far, less 
attention has been paid to the relationship between the dose 
distribution in muscles involved in larynx elevation and tongue 
retraction and the risk of radiation-induced dysphagia. Therefore, the 
purpose of the current study was to investigate the role of the 
radiation dose delivered to the larynx elevation and tongue retraction 
muscles in the development of radiation-induced dysphagia. 
Materials and Methods: This prospective cohort study included 56 
head and neck cancer patients, treated with primary (chemo) 
radiotherapy (CH)RT. In addition to the anatomical structures that 
have been previously identified as swallowing organs at risk (SWOARs), 
such as the PCM superior or supraglottic larynx, muscles involved in 
larynx elevation and tongue retraction were delineated on planning-
CT’s. The larynx elevation complex included an anterior complex, 
including the suprahyoid muscles and thyrohyoid muscle, pharyngeal 
longitudinal muscles and the posterior digastric/ stylohyoid muscles. 
The tongue retraction complex included the genioglossus muscle and 
the tongue base. The primary endpoint was RTOG grade 2-4 dysphagia 
and the secondary endpoints were patient-rated moderate-to-severe 
swallowing problems assessed with the EORTC QLQ-H&N35 
questionnaire, all at 6 months after completing RT of CHRT.  
Results: In the univariate analysis, the mean doses delivered to 
anterior complex (OR=1.116 (95%CI 1.005-1.238)) and longitudinal 
muscles (OR=1.043 (95%CI 1.003-1.085)) were significantly (p≤0.05) 
associated with the primary endpoint. The doses to the anterior 
complex (OR=1.080 (95%CI 1.004-1.162)) and the longitudinal muscles 
were also associated with the risk of moderate-to-severe problems 
with swallowing SOLID food (OR=1.047 (95%CI1.006-1.089)). 
The mean doses delivered to the genioglossus muscle (OR=1.065 
(95%CI 1.002-1.132)) and the base of tongue (OR=1.070 (95%CI 1.005-
1.140)) were also significantly associated with the primary endpoint. A 
significant association was found between the mean dose to the 
genioglossus muscle and problems with swallowing SOLID food 
(OR=1.055 (95%CI 1.002-1.110)). 
Figure 1 shows the NTCP-curves of the risk of grade 2-4 RTOG 
dysphagia and moderate-to-severe problems with solid food as a 
function of the mean dose to these structures. 
 
  
Conclusions: The mean doses delivered to muscles involved in the 
larynx elevation and tongue retraction, as well as the dose to the 
superior PCM and supraglottic larynx, are significantly associated with 
a higher risk of different aspects of radiation-induced dysphagia and 
these structures should also be considered as Swallowing Organs At 
Risk. 
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Purpose/Objective: A wealth of retrospective studies indicate that 
larger tumour volume is a strong prognostic indicator for poor local 
tumour control after (chemo)radiotherapy for laryngeal cancer. The 
impact of tumour volume on the outcome of patients treated within a 
prospective study comparing accelerated radiotherapy (AR) ± 
carbogen breathing and nicotinamide (ARCON) was investigated. 
Materials and Methods: Of 345 patients with cT2-4 laryngeal cancer, 
pre-treatment CT-scans of 270 patients were available for tumour 
volume calculation. Contouring of the primary tumour and involved 
lymph nodes was reviewed by a single head and neck radiation 
oncologist. All living patients had clinical follow-up for a minimum of 
2 years after completion of the treatment. Cox proportional hazard 
models were used for analysis of outcome. 
Results: Of 137 AR and 133 ARCON patients, 57 and 80 vs. 56 and 77 
patients had glottic and supraglottic tumours, respectively (P=0.50). 
Primary tumour and total lymph node volumes were well balanced 
between both treatment arms (P=0.79 and P=0.80, respectively).  
A correlation between the primary tumour volume and T-stage was 
observed (Rs=0.51, P<0.01). In both treatment arms no correlation 
was detected between the primary tumour volume or T-stage and 
